HC Wainwright & Co. Initiates Coverage On Polaryx Therapeutics with Buy Rating, Announces Price Target of $7
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsInitiationPrice Target
HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on Polaryx Therapeutics (NASDAQ:PLYX) with a Buy rating and announces Price Target of $7.
HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on Polaryx Therapeutics (NASDAQ:PLYX) with a Buy rating and announces Price Target of $7.